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ABSTRACT 
Elevated gamma-glutamyl transferase (GGT) levels are associated with higher risk of type 2 
diabetes in observational studies, but the underlying causal relationship is still unclear. Here, 
we tested a hypothesis that GGT levels have a causal effect on type 2 diabetes risk using 
Mendelian randomization. Data were collected from 7,640 participants in a South Korean 
population. In a single instrumental variable (IV) analysis using two stage least squares 
regression with the rs4820599 in the GGT1 gene region as an instrument, one unit of GGT 
levels (IU/L) was associated with 11% higher risk of type 2 diabetes (OR=1.11, 95% CI: 1.04 
to 1.19). In a multiple IV analysis using seven genetic variants that have previously been 
demonstrated to be associated with GGT at a genome-wide level of significance, the 
corresponding estimate suggested a 2.6% increase in risk (OR=1.026, 95% CI: 1.001 to 1.052). 
In a two-sample Mendelian randomization analysis using genetic associations with type 2 
diabetes taken from a trans-ethnic GWAS study of 110,452 independent samples, the single IV 
analysis confirmed an association between the rs4820599 and type 2 diabetes risk (P-
value=0.04); however, the estimate from the multiple IV analysis was compatible with the null 
(OR=1.007, 95% CI: 0.993 to 1.022) with considerable heterogeneity between the causal 
effects estimated using different genetic variants. Overall, there is weak genetic evidence that 
GGT levels may have a causal role in the development of type 2 diabetes. 
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INTRODUCTION 
According to the World Health Organization (1), the number of people diagnosed with type 2 
diabetes has increased consistently in recent decades and has reached 347 million worldwide. 
Type 2 diabetes is a complex metabolic disease influenced by genetic predisposition and 
environmental conditions (2). To better understand the pathogenesis of type 2 diabetes, it is 
important to identify risk factors and their roles in disease development. 
A number of studies have reported that an increased level of gamma-glutamyl transferase (GGT) 
is linked to higher risk of type 2 diabetes (3-8). GGT is an enzyme which catalyzes the transfer 
of gamma-glutamyl groups from glutathione to another acceptors. Since the liver is the major 
site for glucose regulation and detoxification after excess alcohol consumption, GGT is often 
used as a biomarker for the functional state of the liver (9). It has been suggested that the GGT 
level and type 2 diabetes may be biologically linked through circulating insulin level (10, 11), 
oxidative stress (12), and non-alcoholic fatty liver disease (13). However, most existing studies 
on GGT and type 2 diabetes are based on observed associations which do not necessarily imply 
causation because associations may be due to confounding factors, reverse causation, or 
selection bias (14). 
The gold standard approach for causal inference is performing a randomized controlled trial, 
which can be often infeasible. An alternative approach to strengthen causal inference may be 
applying a technique called Mendelian randomization (MR). MR utilizes a genetic variant as 
an instrumental variable (IV) or a proxy of an exposure (or a risk factor). Use of a genetic 
variant (which is randomly assorted at conception, independent of environment) in MR is 
analogous to the random allocation of subjects in a randomized controlled trial (15, 16). 
Assessing the association between the genetic variant and the outcome is analogous to 
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assessing the intention-to-treat effect in a randomized controlled trial, and calculating an IV 
estimate is analogous to estimating the causal effect of the treatment on the outcome in the 
setting of full adherence to the treatment assigned, as in an idealized randomized controlled 
trial. The limitations of MR, including violation of the exclusion criterion or potential genetic 
pleiotropy, have been discussed in detail elsewhere (15, 16, 17).   
Here, we tested a hypothesis that GGT levels have a causal effect on risk of type 2 diabetes 
using MR. Data were collected from 7,640 participants registered in a two-community-based 
cohort within the Korean Genome and Epidemiology study (KoGES). Prior to MR, an 
observational association between measured serum GGT levels and risk of type 2 diabetes was 
estimated using an ordinary least squares (OLS) regression. This step was designed to replicate 
previously reported observation-based association using our data. In a MR framework, we 
considered both single- and multiple- IV analyses. In a single IV analysis, a biologically 
relevant genetic variant was selected as an instrument to assess unconfounded association 
between the estimated (i.e. genetically elevated) GGT levels and risk of type 2 diabetes using 
two stage least squares (2SLS) regression. In multiple IV analyses, genetic variants reported in 
a published GWAS to be robustly associated with GGT levels were selected as multiple 
instruments, with which the association between the estimated (or genetically elevated) GGT 
levels and risk of type 2 diabetes was assessed using three different methods including 2SLS 
regression, inverse-variance weighted (IVW) regression and MR-Egger regression (18).   
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RESULTS 
General characteristics  
General characteristics for a total of 7,640 participants of Korean ancestry are described in 
Table 1. The mean age was 51.98 (± 8.86) years and nearly half of the participants (3,475 
subjects, 45.5%) were male. The proportions of current alcohol drinkers and smokers were 
45.4% and 24.1%, respectively. The mean GGT level was 25.93 (± 20.69) IU/L. Participants 
in the higher quartile group for GGT levels were more likely to be male than female, to live in 
urban areas, to drink more, to smoke more and to have higher levels of type 2 diabetes risk 
factors (including higher values in body mass index (BMI), waist circumference (WC), blood 
pressure, total cholesterol (TC) and triglyceride (TG), and low values in high-density 
lipoprotein (HDL) cholesterol). GGT levels were shown to be associated with type 2 diabetes 
risk (as well as its biomarkers including fasting blood glucose (FBG) and glycated hemoglobin 
(HbA1c)) and the risk of related diseases such as hepatitis, hypertension and dyslipidemia. No 
indication for a U-shaped relationship was observed between GGT levels and type 2 diabetes 
risk based on the quartile group distribution, justifying the use of a linear model in the following 
statistical analyses. 
 
Association between GGT levels and type 2 diabetes risk 
GGT levels were associated with type 2 diabetes risk in OLS analysis (odds ratio (OR)=1.019, 
95% confidence interval (CI): 1.016 to 1.022) (Table 2). This association remained robust after 
adjustment for covariates including age, sex and residential area (OR=1.021, 95% CI: 1.018 to 
1.025) and after further adjustments for potential confounders such as BMI, health behavior 
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and lipid traits (OR=1.017, 95% CI: 1.013 to 1.021). The same pattern of association was 
observed for log2-transformed GGT levels (Supplementary Table S2). 
 
Estimation of causal relationship using a single instrument 
The rs4820599 genetic variant in GGT1, was strongly associated with GGT levels (IU/L), 
validating one IV condition for it to be an instrument (P-value<0.001, F-statistic=16.87 and R-
squared (or variance explained)=0.22%) (Supplementary Table S3).  
This instrument was directly associated with type 2 diabetes risk, suggesting an underlying 
causal relationship (OR=1.19 with a risk allele of G, 95% CI: 1.06 to 1.34) (Supplementary 
Table S4). It appeared this variant was not robustly associated with other type 2 diabetes risk 
factors in the Korean data, including BMI (P-value=0.94), WC (P-value=0.93), TC (P-
value=0.18), TG (P-value=0.56), and HDL cholesterol (P-value=0.52).  
The association between rs4820599 and type 2 diabetes has been reported in a published trans-
ethnic GWAS with 110,180 participants, replicating the suggestive causal relationship 
(OR=1.03 with a risk allele of G, 95% CI: 1.00 and 1.06, P-value=0.04) (19). 
To quantify the causal effect of GGT levels on type 2 diabetes risk, we performed a single IV 
analysis using 2SLS regression in the Korean data. One unit of GGT levels (IU/L), estimated 
using rs4820599, was associated with 11% higher risk of type 2 diabetes (OR=1.11, 95% CI: 
1.04 to 1.19) (Table 3).  
The same pattern was observed for log2-transformed GGT levels (Supplementary Tables S5 
and S6). 
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Estimation of causal relationship using multiple instruments 
In multiple IV analyses, we utilized 7 SNPs having been reported in a large GWAS study of 
East Asian participants for GGT levels by Kim et al. (20). Each of these SNPs was strongly 
associated with GGT levels (IU/L) in our data (Supplementary Table S1) and all of them 
explained 2.1% of variance of GGT levels (IU/L) with an F-statistic of 23.35 under a 
multivariable linear regression model.  
We applied three different methods to quantify causal effects of GGT on type 2 diabetes risk 
using the Korean data: 2SLS, IVW and MR-Egger. With 2SLS regression, one unit of GGT 
levels (IU/L), estimated using 7 SNPs, was weakly associated with 2.5% higher risk of type 2 
diabetes (OR=1.026, 95% CI: 1.001 to 1.052) (Table 4). With IVW, the effect estimate was 
almost unchanged (OR=1.024, 95% CI: 1.001 to 1.048). With MR-Egger, the effect estimate 
was slightly smaller, compatible with the 2SLS and IVW estimates but imprecisely estimated 
(OR=1.018, 95% CI: 0.950 to 1.090) (Table 4). There was little evidence of directional 
pleiotropy in the MR-Egger analysis (P-value for intercept=0.80). 
We then evaluated causal effects in multiple IV analyses through a two-sample approach to 
increase statistical power. SNP effects with GGT levels were taken from the Korean study and 
SNP effects with type 2 diabetes risk were taken from the trans-ethnic GWAS referenced above 
(19). At this stage, 2SLS regression could not be performed as the method requires individual-
level data rather than summarized data. With IVW, the causal effect was essentially null 
(OR=1.007, 95% CI: 0.993 to 1.022). There was substantial heterogeneity in the causal 
estimates based on the 7 SNPs considered individually (Cochan’s Q test: P-value=0.005). With 
MR-Egger, one unit of GGT levels (IU/L) was estimated to lead to 4.6% higher risk of type 2 
diabetes (OR=1.046, 95% CI: 1.012 to 1.082) (Table 5). However, the MR-Egger analysis 
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indicated overall directional pleiotropy (P-value=0.025), and the intercept term from the 
analysis (which, under the MR-Egger assumptions, represent the average pleiotropic effect of 
a SNP) was OR=0.928, an implausibly extreme value as it is larger than the observed genetic 
association with the outcome for any of the individual variants. This means that the 
assumptions necessary for the MR-Egger analysis (in particular, that the pleiotropic effects of 
SNPs are independent of their association with the risk factor) are unlikely to be satisfied. 
Visual inspection of the genetic associations with GGT and Type 2 diabetes risk suggested that 
the 5 variants having the greatest association with GGT had positive causal estimates, whereas 
the 2 variants having smaller associations with GGT had negative causal estimates (Figure 1; 
right panel). This suggests that these SNPs have pleiotropic effects on other variables, as noted 
by some previous studies (20-28). 
For instance, the rs12229654 and rs2074365 variants were shown to be associated with both 
GGT and HDL cholesterol in East Asian populations (20). In several other studies, the 
rs12539316 variant in the genomic region near TBL2-BCL7B had association with TG (20-22) 
and VLDL (23) as well. Also the rs11066453 variant was reported to be associated with 
glycemic traits (24), serum creatinine (25) and waist-hip ratio (26); and the rs2393791 with 
LDL cholesterol, TC (27), and creative protein levels (28). The list of traits associated with 
these SNPs was searched through www.phenoscanner.medschl.cam.ac.uk (Supplementary 
Table S8).   
The same pattern of causal estimates was observed for log2-transformed GGT levels 
(log2(IU/L)) (Supplementary Figures S2 and S3, Supplementary Tables S9 and S10). 
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DISCUSSION 
Here, we used Mendelian randomization to demonstrate that genetically elevated GGT levels 
were associated with high risk of type 2 diabetes. First, in a single IV analysis utilizing the 
rs4820599 genetic variant in GGT1 as an instrument, one unit of GGT levels (IU/L) was 
associated with 11% higher risk of type 2 diabetes in 7,640 South Korean participants (759 
patients and 6,881 controls). This instrument was associated with the risk of type 2 diabetes 
(P-value=0.04) in a published trans-ethnic GWAS study of 110,180 independent participants, 
validating our finding on underlying causal relationship. Next, in a multiple IV analysis 
utilizing 7 independent genetic variants as instruments, one unit of GGT levels (IU/L) was 
weakly associated with 2.6% higher risk of type 2 diabetes in 7,640 South Korean participants. 
This multiple IV analysis was also performed under a two-sample approach (combining 
instrument-exposure associations in 7,640 South Korean participants with instrument-outcome 
associations in up to 110,452 multi-ethnic participants), where one unit of GGT levels (IU/L) 
was associated with 0.7% higher risk of type 2 diabetes by the IVW method, although the 
association was compatible with the null (P-value=0.33). The two-sample estimate from MR-
Egger was large and positive, although implausibly so. There was clear heterogeneity in the 
causal estimates from individual SNPs, with SNPs having greater associations with GGT 
suggesting a positive causal effect of GGT on type 2 diabetes risk, whereas those variants 
having smaller associations with GGT suggested negative causal effects. Both single- and 
multiple- IV analyses provided some evidence of a causal role of elevated GGT levels on the 
development of type 2 diabetes. 
 
Relevance to previous studies 
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Observational associations between circulating GGT levels and risk of type 2 diabetes have 
been reported in several cross-sectional (5, 29, 30) and prospective studies (3, 4, 6-8, 13, 31). 
For instance, a recent meta-analysis of 24 prospective studies suggested that the risk of type 2 
diabetes in the top-third GGT group was 30% higher in comparison with the bottom-third GGT 
group (32).  
There are several biologically plausible mechanisms linking elevated GGT levels and increased 
diabetes risk. For example, metabolic abnormalities accompanied by elevated GGT such as 
insulin resistance (33), obesity (34), and hepatic steatosis (35), may be relevant to development 
of type 2 diabetes. Among these, the relationship between GGT levels and fasting insulin levels 
has been shown as potentially causal in a previous Mendelian randomization study by Conen 
et al. (36). This, in combination with the finding of the current study, can strengthen the 
argument that GGT may play a role in the etiology of type 2 diabetes through insulin level 
changes.  
 
Instrumental variables for GGT 
We utilized the rs4820599 variant of the GGT1 gene as a single instrument. Biochemically, the 
GGT1 gene has a direct functional relevance to GGT levels as it encodes the enzyme that 
catalyzes the transfer of the glutamyl group of glutathione to various amino acids and dipeptide 
receptors, and maintains intracellular glutathione levels (37-39). The rs4820599 variant in 
GGT1 was associated with circulating GGT levels (P-value ~ 10-53) in a large GWAS study 
analyzing a total of 42,940 participants in Asian populations which included 8,842 participants 
from the current study cohort (20). This association remained robust in the current study 
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analyzing a total of 7,640 samples, with F-statistic = 16.87 and R-squared = 0.22%. F-statistic 
of 10 implies that the bias of the IV estimator is 10% of the bias of the observational estimator, 
and is often considered to be minimum strength required to avoid weak instrument bias in IV 
analyses (14, 40). 
Another genetic variant in GGT1, rs2017869, has been utilized as an instrument for GGT levels 
in a previous Mendelian randomization study in relation with fasting insulin levels by Conen 
et al. (36). The rs2017869 variant was in linkage disequilibrium with the rs4820599 variant 
(r2=0.5 based on the 1000 Genome Pilot 1 data with CHB + JPT panel). However, a direct 
comparison between rs4820599 and rs2017869 with regard to the strength as an instrument for 
GGT levels was not feasible in this study, as only rs4820599 was present in our genotype data. 
The rs2017869 variant did not associate with type 2 diabetes risk in the trans-ethnic study (P-
value=0.64).  
Generally it is not straightforward to validate whether the instrument satisfies the no-pleiotropy 
assumption of the IV analysis (such that the rs4820599 variant in GGT1 influences type 2 
diabetes risk only through GGT level changes), although its violation may result in biases in 
causal estimates (15). In the Korean data, the rs4820599 variant appeared not associated with 
risk factors for type 2 diabetes, including BMI, WC, TC, TG and HDL cholesterol, although 
these null associations might be due to insufficient study power. In previous studies, the GGT1 
gene has been shown to be involved in oxidative stress and pro-inflammatory pathways in both 
human and cell/animal, which have a pivotal role in the development of diabetes. Increased 
concentrations of cysteineglycine produced by GGT reaction appeared to generate reactive 
oxygen species, and thus trigger inflammatory responses (41). This may explain the association 
of the rs4820599 variant in GGT1 with chronic pancreatitis (42) and pancreatic carcinogenesis 
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(43), of which the development can be caused by oxidative stress through damaging pancreatic 
cells and stimulating the inflammatory signaling pathway (42). In addition, inflammatory 
cytokines such as tumor necrosis factor α have been shown to regulate the expression of GGT 
through the nuclear factor-b signaling pathway in a human cell system (44). Based on the 
aforementioned studies, one can argue that the pro-inflammatory pathway may be involved in 
a biologically pathogenic link between the GGT gene and type 2 diabetes, will contribute to 
potential pleiotropy of the GGT1 variant on type 2 diabetes in single IV analysis. 
Alternatively, we carried out multiple IV analyses utilizing 7 independent genetic variants as 
instruments. Most of these variants had little known functional relevance to GGT levels, but 
all of them showed strong associations with GGT levels in a large GWAS study (20) as well as 
in the current study. Use of multiple instruments is proposed to interrogate the potential 
pleiotropy of single instruments, as it is unlikely that multiple independent instruments will 
have similar pleiotropic effects (14, 16). Although the recently proposed MR-Egger method 
can improve inferences in some cases, in this example SNPs having different strengths of 
association with the risk factor did not seem to have the same distribution of pleiotropic effects. 
However, the MR-Egger analysis did reveal that SNPs having stronger associations with the 
risk factor did have stronger associations with the disease outcome, as would be expected if 
GGT were a causal risk factor for Type 2 diabetes.  
 
Strengths and limitations of this study 
This is the first study, to our knowledge, which provided evidence for a causal relationship 
between GGT levels and type 2 diabetes risk using an MR approach. This corroborated 
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previous observational studies, and further broadened our knowledge on causal risk factors for 
type 2 diabetes.  
We acknowledge several limitations of our study. First, use of multiple instruments, selected 
from the GWAS study that included the current study sample as well as other independent 
sample (19), may cause an over-fitting bias (such that the IV estimation of exposure-outcome 
association is biased towards the confounded association) (40, 45). However, these multiple 
instruments were strongly associated with GGT levels; p-values had magnitudes of 10-14, 10-30, 
10-58, 10-126, 10-44 and 10-53 in Kim et al. and 10-5, 10-4, 10-20, 10-31, 10-8 and 10-7 in the current 
study, respectively, as shown in the Supplementary Table 1. (It should be noted that the GGT 
values were transformed differently in these studies, with inverse square root transformation in 
Kim et al. and no transformation in the current study. Thus, a direct comparison of effect sizes 
was not feasible.) The main reason for the smaller p-value in Kim et al. should be its larger 
sample size and consequently an increased study power (n = up to 28,367 in Kim et al. and 
7,640 in the current study). As the instrument-exposure associations were robust across 
independent cohorts, there is less chance of a selection bias due to over-fitting in the current 
study. 
Secondly, several of the SNPs used in the multiple IV analysis are known to be pleiotropic as 
shown in the Supplementary Table S8. While some of the SNPs have clear associations with 
Type 2 diabetes risk, the directions of these associations were not consistent. Also there was 
clear heterogeneity in the causal estimates calculated using the individual SNPs. This means 
there is not a consistent picture of causality evidenced by all these SNPs even though the 
variants having greater associations with GGT were the ones suggesting a positive causal effect 
of GGT on Type 2 diabetes risk. 
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Thirdly, odds ratios in this study differ depending on the methods used. This is because different 
methods calculate odds ratios differently. The odds ratio in a multivariate logistic model 
measures an individual effect of a unit increase in the risk factor onto the outcome conditional 
on covariates included in the model. On the other hand, the odds ratio in Mendelian 
randomization measures a value close to the population-average effect of a unit increase in the 
risk factor onto the outcome marginal across covariates, the effect that one would expect to 
estimate in an idealized randomized controlled trial (46). Another reason for differences 
between estimates is that Mendelian randomization estimates reflect the effects of long-term 
(often life-long) changes in the risk factor, whereas observational estimates reflect the 
difference in the outcome related to measurement of the risk factor at a single point in time. 
Mendelian randomization estimates therefore tend to be larger than observational estimates 
(47). Although the discrepancy in odds ratio estimates by different methods is somewhat 
expected, the single IV based odds ratio in this study is particularly greater than the other 
estimates. This may be because of a potential pleiotropic effect of the single IV, rs4820599, 
given that the odds ratio in a multiple IV analysis overlaps with the odds ratios in multivariate 
logistic models. Nevertheless, it should be noted that all reported odds ratios suggest the same 
direction of association between elevated GGT levels and increased type 2 diabetes risk.  
Lastly, diagnoses of disease were based on self-reported examinations. However, to minimize 
the proportion of undiagnosed type 2 diabetes patients and gain more precise classification, we 
took into account the related phenotype data regarding medication history, FBG levels, or 
HbA1c levels.  
 
In conclusion, there is some genetic evidence for causal relationships between elevated GGT 
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levels and increased risk of type 2 diabetes in the general Korean population. Modulation of 
GGT levels, for example, by diet or pharmacologic intervention, may be worth further 
investigation to establish if it could be a useful strategy in type 2 diabetes prevention. 
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MATERIALS AND METHODS 
Study population 
The study population consisted of subjects who were registered in the Ansung and Ansan 
cohorts of the KoGES consortium from 2001 to 2003. The KoGES was established to discover 
new biomarkers and investigate risk factors for chronic diseases such as diabetes, hypertension, 
and dyslipidemia in individuals aged 39-70 years from the general Korean population. Among 
10,038 participants initially recruited, only 7,640 were included in the current study after 
removing 1,196 due to poor genotyping, 863 due to missing data for key variables (including 
GGT (n=1), FBG (n=260), blood pressure (n=6), and main SNPs (n=596)), and additional 339 
due to outlying GGT levels (more than 2 standard deviations away from the mean (SD)). All 
participants completed a written consent form and agreed with the Human Subjects Review 
Committee at the Korea University Ansan Hospital or the Ajou University Medical Center. 
This study was approved by the Committee on the Institutional Review Board of the Korea 
University. 
 
General characteristics 
Sociodemographic variables included age, sex, residential area, physical activity, smoking 
status, and alcohol consumption. The residential area was divided into two: rural Ansung and 
urban Ansan. Age was used as a categorical variable (<50, 50-59 and ≥60). Physical activity 
was classified according to intensity as follows: sedentary activity for less than 30 minutes per 
day, and light, moderate, and intense activity for 30 minutes to more than 5 hours. Participants 
were grouped into never, previous and current smokers with respect to their smoking status. 
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Similarly, subjects were categorized as never, previous and current drinkers. For drinkers, the 
amount of alcohol consumption per day was requested. Biochemical variables included BMI, 
WC, blood pressure, lipid levels, FBG, HbA1c, and GGT. BMI (kg/m
2) was calculated by 
dividing the weight (kg) by the height squared (m2), and classified as follows: <18.5, 
underweight; ≥18.5 and <25, normal; ≥25, obese. WC (cm) was calculated as the average of 3 
measurements. Blood pressure was measured in a sitting position and the higher value between 
the left and right arms was used. The levels of TC (mg/dL), TG (mg/dL), HDL cholesterol 
(mg/dL), FBG (mg/dL), HbA1c (%, mmol/mol), and GGT (IU/L) were measured in Seoul 
Clinical Laboratories (Seoul, Republic of Korea) from overnight fasted blood samples. 
 
Definition of diabetes and other diseases 
Diagnosis of diseases such as cardiovascular disease (CVD), hepatitis, hypertension, 
dyslipidemia, and type 2 diabetes was based on self-reported medical history. Subjects who 
had been diagnosed with type 2 diabetes before or under treatment with drugs or insulin 
injections, and who had been undiagnosed but having FBG levels higher than 126 mg/dL or 
HbA1c levels higher than 6.5% were regarded as diabetes cases. Subjects who were diagnosed 
with myocardial infarction, congestive heart failure, coronary artery disease, peripheral blood 
vessel disease, and cerebrovascular disease were regarded as CVD cases. 
 
DNA genotyping and imputation 
Genomic DNA was extracted from peripheral blood samples of subjects using the QuickGene 
DNA Whole Blood Kit S with QuickGene-810 equipment (Fujifilm, Tokyo, Japan). Genomic 
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DNA (500 ng) was analyzed using the Affymetrix Genome-Wide SNP Array 5.0 (Affymetrix, 
Inc., Santa Clara, CA, USA). The Bayesian robust linear modeling with Mahalanobis distance 
genotyping algorithm was used to calculate the accuracy of genotyping. Detailed information 
can be found elsewhere (45). Individuals with a high missing genotype call rate, high 
heterozygosity, gender inconsistencies and any kind of diagnosed cancer were excluded. In 
addition, SNPs with a high missing genotype call rate (>5%), low minor allele frequency 
(<0.01), and out of Hardy-Weinberg equilibrium (P value <1.0x10-6) were excluded, leaving 
352,228 SNPs available for analysis in 8,842 subjects. Additional SNP markers were then 
imputed from a HapMap reference panel consisting of 3.99 million SNPs (HapMap release 22) 
in 90 individuals from Japanese (JPT) and Chinese (CHB) populations, by the IMPUTE 
software (49, 50). After imputation, SNPs with minor allele frequency <0.01 or information 
score <0.3 were removed due to low quality, leaving a total of 1,804,397 SNPs available for 
the current study (352,228 SNPs of these were directly genotyped). 
 
Statistical analysis 
All statistical analyses were performed using SPSS v.21.0, Stata v.12 and R v.3.1.2. General 
characteristics of the participants were described as mean ± SD for continuous variables and 
frequency (%, n) for categorical variables. Differences according to the quartiles of GGT levels 
were tested by one-way ANOVA for continuous variables and by chi-squared tests for 
categorical variables. The distribution of each variable was visually inspected and the TG levels 
were log-transformed with base 10 to mimic Gaussian distribution. For GGT, both the 
untransformed values (IU/L) and the log-2 transformed values (log2(IU/L)) were used for 
further statistical analyses. 
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Observational association. Observational association between GGT levels and type 2 diabetes 
risk was assessed under a logistic regression model with OLS estimation. Covariates were 
considered including age, sex, area, smoking status, alcohol intake, physical activity, BMI, and 
lipid levels, as the latter would reduce skewness. 
Single IV analysis. To assess a causal association in GGT1 was selected as an instrument for 
GGT, due to its clear biological relevance (37-39). We first measured association of this 
instrument with GGT and with type 2 diabetes risk directly using a logistic regression, to 
quantify the instrument strength and to validate the extent of causal association, respectively. 
Next, the causal effect of GGT on type 2 diabetes risk was quantified by 2SLS. In the first stage 
of 2SLS, the GGT value was regressed on this instrument using a linear regression model. In 
the second stage of 2SLS, the type 2 diabetes risk was regressed on the fitted GGT value 
obtained from the first stage using logistic regression. In both stages of 2SLS, we considered 
age, sex and area as covariates. 
Replication of single IV analysis. Replication of association between the single instrument and 
type 2 diabetes was attempted by looking into summary statistics in Mahajan et al., the latest 
independent GWAS study on type 2 diabetes (19). The samples used in Mahajan et al., from 
up to 110,452 participants (83,964 controls and 26,488 cases) in multiethnic background (19), 
are not overlapping with the samples of the current study. Summary statistics from this 
publication of association between genetic variants and type 2 diabetes risk were available at 
http://diagram-consortium.org/.  
Selection of multiple instruments. To select multiple instruments, we reviewed SNPs robustly 
associated with GGT levels in two largest GWAS studies (20, 51). Chambers et al. (51) reported 
a total of 26 SNPs associated with GGT levels in participants of European and Indian Asian 
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ancestry; and Kim et al. (20) reported a total of 7 SNPs for GGT levels in East Asian 
populations (Supplementary Table S1). Among these, three loci (ZNF827, HNF1A and GGT1) 
were reported in both studies. We first checked data availability; only 8 SNPs out of 26 in 
Chambers et al. (51) and all 7 SNPs in Kim et al. (20) were present in our genotype data. We 
then compared ancestry; our study samples had the same East Asian ancestry than those in Kim 
et al.. Failure of matching on ancestry may result in bias in IV estimation because the random 
allocation of alleles of IVs can be affected by population structure conditional on ancestry (15). 
Hence, due to the higher percentage of available SNPs and matching ancestry, the 7 SNPs in 
Kim et al. (20) were selected as instruments in our multiple IV analyses. These 7 SNPs included 
the rs4820599 genotype in GGT1, a single instrument in the previous single instrument based 
Mendelian randomization.  
Nevertheless, it should be noted that the GWAS study by Kim et al. analyzed a subset of the 
current study samples (20). Out of a total of 42,940 samples in Kim et al. (20), about 20% 
(n=8,842) were from the KoGES cohort, the same cohort of the current study. This might result 
in “over-fitting” problem such that the IV estimation of exposure-outcome association may be 
biased towards the confounded association, when the instrument-exposure and instrument-
outcome associations were estimated from the same cohorts (40, 45). 
Multiple IV analysis. For multiple IV analysis, we applied a conventional 2SLS regression, 
IVW regression and recently proposed MR-Egger regression (18). The 2SLS regression was 
carried out as follows: in the first stage, the GGT levels were predicted by 7 SNPs (as well as 
covariates including age, sex and area) which was then used as a predictor for type 2 diabetes 
risk in the second stage. Prior to IVW and MR-Egger, the association of each of 7 SNPs on 
GGT and the association of each of 7 SNPs on type 2 diabetes risk were estimated under a 
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linear regression model adjusting for age, sex and area. We then regressed the coefficients of 7 
SNPs on type 2 diabetes risk on the coefficients of 7 SNPs on GGT levels in which the slope 
estimate was interpreted as the overall causal effect estimate of GGT on type 2 diabetes risk, 
using IVW and MR-Egger regression models, as shown in Bowden et al. (18). At this stage, 
the sign of coefficients of 7 SNPs on GGT levels was all positively aligned before regression. 
Contrary to IVW, MR-Egger allows a non-zero intercept estimate which can indicate an 
average pleiotropic effect of multiple instruments. IVW and MR-Egger have different model 
assumptions. IVW is asymptotically the same as 2SLS and performs well under the three IV 
assumptions (18). On the other hand, the recently proposed MR-Egger performs under relaxed 
IV assumptions, where the IV assumption on pleiotropy can be substituted to a weaker InSIDE 
(Instrument Strength Independent of Direct Effect) assumption (that is, there is no correlation 
between the effects of genetic variants on the exposure and the direct effects of genetic variants 
on the outcome that are not mediated by the exposure). This implies that MR-Egger provides 
a robust estimate of the causal effect in comparison to the IVW method, even in the case where 
there is directional pleiotropy (18). It should be noted that the P-value and the confidence 
interval of the IVW estimates were calculated using a Z-test in order that these estimates could 
be directly comparable with the 2SLS estimates. 
Multiple IV analysis under a two-sample approach. To increase the power of multiple IV 
analysis, we applied a two-sample analysis approach which basically combines the instrument-
exposure association estimated in the current study with the instrument-outcome association 
reported in the published larger study (52, 53). Similarly to our single IV analysis, we looked 
into findings in a large GWAS for type 2 diabetes by Mahajan et al. (19) to get summary 
statistics of association between each of 7 instruments and type 2 diabetes (with up to 83,964 
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controls and 26,488 cases in multiethnic background) (19). Summary statistics from this 
publication were downloaded from http://diagram-consortium.org/.  
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Figure legend 
 
Figure 1 Multiple IV analyses: Inverse-variance weighted estimates and MR-Egger estimates 
of GGT to diabetes risk with 7 SNPs as instruments, in the Korean data (left) and under a two-
sample approach (right) 
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Table 1 Baseline characteristics of the participants according to quartiles of GGT level 
 
All participants  
(n=7,640) 
GGT (IU/L) 
P-value Q1  
(n=1,727) 
Q2  
(n=2,188) 
Q3  
(n=1,824) 
Q4  
(n=1,901) 
Age (years) 51.98 ± 8.86 51.07 ± 9.05 52.82 ± 8.95 52.39 ± 8.78 51.42 ± 8.54 <0.001 
Male %, (n) 45.5 (3,475) 10.4 (179) 31.3 (684) 60.3 (1,099) 79.6 (1,513) <0.001 
Area %, (n)      
   Urban (Ansan) 54.2 (4,144) 49.4 (853) 50.1 (1,097) 58.4 (1,065) 59.4 (1,129) 
<0.001 
   Rural (Ansung) 45.8 (3,496) 50.6 (874) 49.9 (1,091) 41.6 (759) 40.6 (772) 
Physical exercise %, (n)      
   Lowest 6.2 (470) 4.1 (70) 4.9 (105) 6.5 (118) 9.4 (177) 
<0.001 
   Lower middle 37.1 (2,795) 37.2 (632) 37.5 (806) 36.9 (665) 36.7 (692) 
   Upper middle 23.3 (1,752) 25.0 (425) 22.4 (483) 24.1 (435) 21.7 (409) 
   Highest 33.4 (2,517) 33.6 (570) 35.2 (758) 32.4 (584) 32.1 (605) 
Alcohol drinker %, (n)      
   Never 48.1 (3,639) 71.8 (1,223) 59.2 (1,281) 40.2 (729) 21.5 (406)  
   Previous 6.5 (494) 4.0 (68) 6.3 (137) 8.7 (157) 7.0 (132) <0.001 
   Current 45.4 (3,440) 24.2 (413) 34.5 (747) 51.1 (926) 71.6 (1,354)  
Alcohol (g/day) 8.25 ± 19.82 1.16 ± 5.13 3.09 ± 10.14 8.85 ± 18.33 20.05 ± 29.98 <0.001 
Smoker %, (n)      
    Never 60.8 (4,583) 90.3 (1,527) 73.2 (1,576) 49.7 (896) 30.9 (584)  
   Previous 15.1 (1,136) 3.8 (64) 11.6 (249) 20.2 (364) 24.3 (459) <0.001 
    Current 24.1 (1,817) 5.9 (100) 15.3 (329) 30.1 (543) 44.7 (845)  
BMI (kg/m2) 24.60 ± 3.13 23.75 ± 2.93 24.35 ± 3.12 25.02 ± 3.17 25.28 ± 3.05 <0.001 
WC (cm) 82.44 ± 8.83 78.74 ± 8.82 81.23 ± 8.86 83.96 ± 8.29 85.75 ± 7.68 <0.001 
Blood pressure (mmHg)      
    Systolic 124.09 ± 18.80 119.89 ± 18.98 123.33 ± 18.96 125.35 ± 18.32 127.56 ± 18.10 <0.001 
    Diastolic 81.43 ± 11.83 77.81 ± 11.85 80.60 ± 11.64 82.39 ± 11.41 84.73 ± 11.41 <0.001 
TC (mg/dL) 191.59 ± 35.40 177.47 ± 30.25 191.56 ± 34.02 195.29 ± 35.00 200.92 ± 37.66 <0.001 
HDL (mg/dL) 44.65 ± 9.94 45.74 ± 9.61 45.39 ± 10.06 43.56 ± 9.90 43.84 ± 9.98 <0.001 
TG (mg/dL) 157.08 ± 95.64 121.49 ± 53.80 139.96 ± 75.28 162.87 ± 89.59 203.54 ± 127.46 <0.001 
FBG (mg/dL) 87.19 ± 21.38 81.29 ± 13.52 85.27 ± 19.14 88.48 ± 19.91 93.54 ± 28.13 <0.001 
HbA1c (%) 5.74 ± 0.82 5.54 ± 0.54 5.66 ± 0.69 5.82 ± 0.86 5.94 ± 1.03 <0.001 
HbA1c 
(mmol/mol) 
39 ± 9 37 ± 6 38 ± 8 40 ± 9 41 ± 11 <0.001 
GGT (IU/L) 25.93 ± 20.69 9.37 ± 1.33 14.60 ± 1.96 24.37 ± 3.97 55.52 ± 20.59 <0.001 
Disease diagnosis %, (n)      
   Hepatitis 4.2 (318) 3.5 (60) 3.2 (70) 4.6 (83) 5.5 (105) 0.001 
   Hypertension 15.1 (1,151) 9.0 (155) 15.0 (328) 18.1 (331) 17.7 (337) <0.001 
   Dyslipidemia 2.4 (182) 1.2 (20) 1.6 (34) 3.5 (63) 3.4 (65) <0.001 
   CVD 3.1 (237) 2.1 (36) 3.1 (67) 3.8 (69) 3.4 (65) 0.025 
   Type 2 diabetes 4.5 (343) 1.9 (33) 2.9 (63) 5.9 (108) 7.3 (139) <0.001 
The values were described as mean ± SD for a continuous variable, and as frequency (n) for a categorical variable. Difference among 
GGT categories was evaluated by one-way ANOVA for continuous variables, and by chi-squared tests for categorical variables. 
BMI, Body mass index; WC, Waist circumference; TC, Total cholesterol; HDL, High-density lipoprotein; TG, Triglyceride; FBG, 
Fasting blood glucose; HbA1c, glycated hemoglobin; GGT, gamma-glutamyl transferase; CVD, Cardio vascular disease. 
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Table 2 Observational association: Ordinary least squares estimates of GGT to type 2 diabetes risk 
  
Type 2 diabetes 
(n=6,881 for control, 759 for case) 
OR (95% CI)  
by OLS estimation 
P-value 
GGT (IU/L) 
 
Unadjusted 1.019 (1.016, 1.022) <0.001 
Model a 1.021 (1.018, 1.025) <0.001 
Model b 1.020 (1.017, 1.024) <0.001 
Model c 1.017 (1.013, 1.021) <0.001 
Model a was adjusted for age, area, and sex. Model b was adjusted for age, area, sex, alcohol use, smoking status, physical activity, 
and BMI. Model c was adjusted for age, area, sex, alcohol use, smoking status, physical activity, BMI, TC, log10-transformed TG, 
and HDL. 
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Table 3 Single IV analysis in the Korean data: Two stage least squares estimates of GGT to type 2 diabetes 
risk with rs4820599_G as an instrument  
 
Type 2 diabetes 
(n=6,881 for control, 759 for case) 
OR (95% CI)  
by single IV estimation 
P-value 
GGT (IU/L) 2SLS 1.11 (1.04, 1.19) 0.003 
2SLS was adjusted for age, area, and sex.  
 
Table 4 Multiple IV analysis in the Korean data: Two stage least squares estimates, inverse-variance weighted 
estimates and MR-Egger estimates of GGT to type 2 diabetes risk with 7 SNPs as instruments  
 
Type 2 diabetes 
(n=6,881 for control, 759 for case) 
Intercept Estimate 
(SE, P value)  
Slope Estimate  
(SE, P value) 
OR (95% CI)  
by multiple IV estimation 
P-value 
GGT (IU/L) 
2SLS - - 1.026 (1.001, 1.052) 0.042 
IVW Constrained to 0 
0.024  
(0.012, P=0.044) 
1.024 (1.001, 1.048) 0.044 
MR-Egger 
0.018  
(0.066, P=0.798) 
0.017  
(0.027, P=0.540) 
1.018 (0.950, 1.090) 0.540 
2SLS was adjusted for age, area, and sex. 7 SNP effects on GGT and type 2 diabetes, used in IVW and MR-Egger, were reported in 
Supplementary Table S7.   
 
Table 5 Multiple IV analysis under a two sample approach: Inverse-variance weighted estimates and MR-
Egger estimates of GGT to type 2 diabetes risk with 7 SNPs as instruments  
 
Type 2 diabetes 
(under a two-sample approach*)  
Intercept Estimate 
(SE, P value) 
Slope Estimate 
(SE, P value) 
OR (95% CI)  
by multiple IV estimation 
P-value 
GGT(IU/L) 
IVW Constrained to 0 
0.007  
(0.007, P=0.332) 
1.007 (0.993, 1.022) 0.332 
MR-Egger 
-0.075  
(0.024, P=0.025) 
0.045  
(0.013, P=0.017) 
1.046 (1.012, 1.082) 0.017 
7 SNP effects on GGT and type 2 diabetes, used in IVW and MR-Egger, were reported in Supplementary Table S7. *SNP effects on 
GGT were estimated in the Korean data (n=7,640) and SNP effects on type 2 diabetes risk were estimated in a trans-ethnic GWAS 
(n≤83,964 for control, 26,488 for case).   
  
35 
 
ABBREVIATIONS 
2SLS; 2Stage least square 
BMI; Body Mass Index 
CI; Confidence interval 
CVD; Cardio vascular disease 
FBG; Fasting blood glucose 
GGT; gamma-glutamyl transferase 
GWAS; Genome-wide association study 
HbA1c; Glycated hemoglobin 
HDL; High-density lipoprotein 
IV; Instrument variable  
IVW; Inverse-variance weighted 
KoGES; Korean Genome and Epidemiology Study 
MR; Mendelian randomization 
OLS; Ordinary least square 
OR; Odds ratio 
SD; Standard deviation  
SE; Standard error 
SNP; Single nucleotide polymorphism 
TC; Total cholesterol 
TG; Triglyceride 
WC; Waist circumference 
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